Biocartis

Biocartis is an innovative commercial stage molecular diagnostics company providing next generation diagnostic solutions.

  • With an initial market cap of €450m, Biocartis' IPO on Euronext Brussels is the largest Life Sciences IPO on Euronext since 2005
  • Proceeds of the IPO will be used to support R&D and to strengthen sales & marketing capabilities
  • Kempen & Co acted as Joint Bookrunner in the offering with demand exceeding €650m
 
Disclaimer Kempen Privacy statement Kempen Disclaimer Kempen & Co Privacy statement Kempen & Co Statement under the UK Modern Slavery Act Cookie statement & settings
Kempen & Co is a trade name of Van Lanschot Kempen NV. Kempen Capital Management NV is part of Van Lanschot Kempen NV.